Our Story
Our mission: To improve human health and quality of life by transforming the way therapeutics and materials are discovered.
With steadfast investment in R&D, we continue to develop and refine our scientific platform. Our platform is deployed by users worldwide to enable the discovery of novel therapeutics and materials more rapidly, at a lower cost, and we believe with a higher likelihood of success. It is also the foundation of our internal drug discovery initiatives to develop first-in-class therapies.
Schrödinger through the years
EXPLORE
1990
Co-founders Richard Friesner and Bill Goddard launch Schrödinger

1992
First software sale, to Brookhaven National Laboratory

1995
First investment from David E. Shaw

2001
Release Glide, which offers high-throughput virtual screening of millions of compounds

2003
Release Prime, a fully integrated protein structure prediction program

2009
Release WaterMap, the first rigorous method for computing protein-bound water locations and energetics


2010
First investment from Bill Gates


2012
Launch Materials Science division

2014
Release FEP+, the first benchmark method for accurately predicting binding affinity differences among molecules with a common core


2016
Launch collaboration with Sanofi to support drug discovery with computational resources


2017
Launch research collaboration with Takeda to accelerate drug discovery

2018
Launch Cryo-EM Initiative to join global research centers in leveraging cryo-electron microscopy


2019
Co-found Faxian Therapeutics drug development company with WuXi AppTec


2020
Initial Public Offering
